Free Trial
Courtney Breen

Courtney Breen Analyst Performance

Senior Research Analyst at Sanford C. Bernstein

Courtney Breen is a stock analyst at Sanford C. Bernstein in the medical sector, covering 4 publicly traded companies. Over the past year, Courtney Breen has issued 7 stock ratings, including buy and hold recommendations. While full access to Courtney Breen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Courtney Breen's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
7 Last 0 Years
Buy Recommendations
71.43% 5 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy71.4%5 ratings
Hold28.6%2 ratings
Sell0.0%0 ratings

Out of 7 total stock ratings issued by Courtney Breen at Sanford C. Bernstein, the majority (71.4%) have been Buy recommendations, followed by 28.6% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
2 companies
NASDAQ
50.0% of companies on NASDAQ
2 companies

Courtney Breen, an analyst at Sanford C. Bernstein, currently covers 4 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Courtney Breen of Sanford C. Bernstein specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
2 companies
50.0%
MED - BIOMED/GENE
2 companies
50.0%

Courtney Breen's Ratings History at Sanford C. Bernstein

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
3/10/2026Reiterated Rating$1,002.19Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/11/2026Reiterated Rating$155.13$160.00Outperform
Amgen Inc. stock logo
AMGN
Amgen
1/20/2026Downgrade$328.65$335.00Market Perform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
12/29/2025Set Price Target$124.72$135.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/19/2025Reiterated Rating$1,067.63Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
11/24/2025Boost Price Target$1,058.05$1,300.00Outperform
Pfizer Inc. stock logo
PFE
Pfizer
10/31/2025Reiterated Rating$24.42$30.00Market Perform